Close Menu

NEW YORK – Medicare Administrative Contractors CGS Administrators and Wisconsin Physicians Service Insurance Corporation released final coverage decisions aligning with Palmetto's limited coverage of minimal residual disease testing in patients with colorectal cancer.

The evidence review for the decisions centered specifically on Natera's Signatera test, although other ctDNA tests that meet the requirements would also be covered.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.